CODEX DNA INC (DNAY)

US1920031010 - Common Stock

1.3  +0.1 (+8.33%)

Fundamental Rating

2

Taking everything into account, DNAY scores 2 out of 10 in our fundamental rating. DNAY was compared to 58 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of DNAY have multiple concerns. DNAY is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

DNAY had negative earnings in the past year.
In the past year DNAY has reported a negative cash flow from operations.

1.2 Ratios

DNAY has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

DNAY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

DNAY does not have a ROIC to compare to the WACC, probably because it is not profitable.
DNAY has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, DNAY has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -2.00, we must say that DNAY is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of DNAY (-2.00) is worse than 83.08% of its industry peers.
A Debt/Equity ratio of 0.37 indicates that DNAY is not too dependend on debt financing.
DNAY has a Debt to Equity ratio of 0.37. This is comparable to the rest of the industry: DNAY outperforms 41.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Altman-Z -2
ROIC/WACCN/A
WACC10.64%

2.3 Liquidity

A Current Ratio of 4.86 indicates that DNAY has no problem at all paying its short term obligations.
DNAY has a Current ratio (4.86) which is in line with its industry peers.
DNAY has a Quick Ratio of 4.68. This indicates that DNAY is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.68, DNAY perfoms like the industry average, outperforming 58.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.86
Quick Ratio 4.68

More info and screens

4

3. Growth

3.1 Past

DNAY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -63.94%.
The Revenue has grown by 112.52% in the past year. This is a very strong growth!
EPS 1Y (TTM)-63.94%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-23.53%
Revenue 1Y (TTM)112.52%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q139.59%

3.2 Future

Based on estimates for the next years, DNAY will show a small growth in Earnings Per Share. The EPS will grow by 0.26% on average per year.
The Revenue is expected to grow by 65.78% on average over the next years. This is a very strong growth
EPS Next Y-6.4%
EPS Next 2Y5.24%
EPS Next 3Y7.97%
EPS Next 5Y0.26%
Revenue Next Year106.09%
Revenue Next 2Y97.94%
Revenue Next 3Y85.04%
Revenue Next 5Y65.78%

3.3 Evolution

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DNAY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DNAY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.24%
EPS Next 3Y7.97%

More info and screens

0

5. Dividend

5.1 Amount

DNAY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CODEX DNA INC

NASDAQ:DNAY (1/3/2023, 7:00:01 PM)

1.3

+0.1 (+8.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap38.38M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.86
Quick Ratio 4.68
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-63.94%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-6.4%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)112.52%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y